Qfitlia

Oct 16, 2026

Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...

Aug 22, 2025

Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by E...

Apr 07, 2025

Over the past three years, the FDA has approved six new hemophilia treatments, including three gene therapies. Now, Sanofi’s Qfitlia (fitusiran) enters the competitive hemophilia therapeutics market, distinguishing itself as the only therapy approved for all types of hemophilia. Unlike most existing treatments, Qfi...